Long-term safety and efficacy of continuous acitretin monotherapy for three children with different severe hyperkeratotic disorders in China

J Dermatol. 2018 Aug;45(8):1003-1008. doi: 10.1111/1346-8138.14462. Epub 2018 May 14.

Abstract

Long-term systemic treatment with acitretin for severe hyperkeratotic disorders is needed to maintain quality of life of afflicted patients, but treatment has been limited owing to its potential side-effects including skeletal malformations, particularly for children during their growth and development. A retrospective investigation was conducted with three children afflicted with a severe hyperkeratotic disorder, namely Darier's disease, bullous ichthyosiform erythroderma or lamellar ichthyosis, who were continuously maintained on 0.2-0.3 mg/kg per day acitretin for more than 12 years after an initial period at a larger acitretin dose to bring each disease under control. The patients had good responses to acitretin treatment, which was assessed for safety, skeletal abnormalities, growth retardation and other potential side-effects. Acitretin monotherapy was an effective treatment for these children, and maintenance doses were well tolerated with no skeletal or other observable side-effects during the course of the study.

Keywords: Darier's disease; acitretin; bullous ichthyosiform erythroderma; hyperkeratotic disorders; lamellar ichthyosis.

Publication types

  • Case Reports

MeSH terms

  • Acitretin / pharmacology
  • Acitretin / therapeutic use*
  • Administration, Oral
  • Adolescent
  • Biopsy
  • China
  • Darier Disease / drug therapy*
  • Darier Disease / pathology
  • Dose-Response Relationship, Drug
  • Humans
  • Hyperkeratosis, Epidermolytic / drug therapy*
  • Hyperkeratosis, Epidermolytic / pathology
  • Ichthyosis, Lamellar / drug therapy*
  • Ichthyosis, Lamellar / pathology
  • Keratolytic Agents / pharmacology
  • Keratolytic Agents / therapeutic use*
  • Long-Term Care / methods
  • Male
  • Quality of Life
  • Skin / pathology
  • Treatment Outcome
  • Young Adult

Substances

  • Keratolytic Agents
  • Acitretin